#### Warning

This fact sheet aims to let you know the side effects most commonly seen following the administration of your treatment. Please note that when you take any medication, there is a possibility that it causes rare side effects and it is difficult to predict which patients will be affected.

# General information for patient Bevacizumab

Date: June 2018 Revision:

Medication	Administration
Bevacizumab	Intravenous infusion on day(s) of chemotherapy cycle
	1 <sup>st</sup> infusion: 90 minutes
	2 <sup>nd</sup> infusion: 60 minutes *
	3 <sup>rd</sup> infusion: 20 to 30 minutes *
	* if previous treatment well tolerated
Cycle is repeated every weeks	

This fact sheet has been prepared by a sub-committee of the Comité national de l'évolution de la pratique des soins pharmaceutiques of the Direction générale de cancérologie of the Ministry of Health and Social Services in consultation with the Comité de l'évolution de la pratique en oncologie of the Institut national d'excellence en santé et en services sociaux.

### General Information associated with your treatment

- > Bevacizumab is used in combination with chemotherapy to treat certain types of cancer. It is a monoclonal antibody which enhances the efficacy of your chemotherapy.
- > A **blood test**, a urinary analysis as well as a measurement of your blood pressure will be done prior to every cycle of treatment.
- Bevacizumab administered during pregnancy may harm the embryo. A method of contraception is strongly recommended during treatment and for 6 months after the last dose. Breast-feeding is contra-indicated during treatment.
- Consult your doctor or pharmacist before you take other medications (even over the counter medications available without a prescription) or **natural health products** or if you need to receive a **vaccine**. These may provoke an interaction with your treatment and diminish its efficacy or increase side effects.
- It is very important to notify us if you start taking medications such as Aspirin<sup>®</sup>, blood thinners (ex: Coumadin<sup>®</sup>...), anti-inflammatory drugs (ex: Motrin<sup>®</sup>, Advil<sup>®</sup>...)
- Follow the instructions given by your cancer center about the right way to handle and dispose of biological fluids (for example urine, stools) in order to protect the environment and your relatives.
- Be sure to always have on hand the complete list of your medications, dietary supplements, vitamins and other natural health products. Give it to your doctor and your pharmacist. It is important to make them aware of any change.

This fact sheet has been prepared by a sub-committee of the Comité national de l'évolution de la pratique des soins pharmaceutiques of the Direction générale de cancérologie of the Ministry of Health and Social Services in consultation with the Comité de l'évolution de la pratique en oncologie of the Institut national d'excellence en santé et en services sociaux.

### Warning

## Adverse effects and their management

Adverse effects	Management
We suggest that you consult the pamphlet w	in combination with chemotherapy. vhich describes the specific information regarding otherapy regimen.
Minor bleeding such as nose bleed may occur.	1,7 0
High blood pressure might develop.	<ul> <li>Before each treatment, your nurse will measure your blood pressure.</li> <li>If you experience high blood pressure, medications can be prescribed to control it.</li> </ul>
Abdominal pain can occur.	<ul> <li>Notify your physician or pharmacist if this happens.</li> <li>If you experience severe, sudden pain with nausea, vomiting or constipation, go to the Emergency Room immediately.</li> </ul>
Rare adverse effects that can be severe o	or serious to communicate quickly to your doctor
<b>If you experience any of the following</b> <b>symptoms:</b> Severe headache, visual problems, difficulty talking, loss of coordination, weakness or numbness, chest pain or chest tightness.	<ul> <li>Go immediately to the Emergency Room.</li> </ul>
Special (	Consideration
<ul> <li>Notify your dentist or physician that you a surgery while on treatment.</li> </ul>	are receiving bevacizumab if you have to undergo

This fact sheet has been prepared by a sub-committee of the Comité national de l'évolution de la pratique des soins pharmaceutiques of the Direction générale de cancérologie of the Ministry of Health and Social Services in consultation with the Comité de l'évolution de la pratique en oncologie of the Institut national d'excellence en santé et en services sociaux.